Oral Health in Africa: Promoting Collaborative Solutions

By Crystal Lubbe

April 1, 2025

Is oral health taking a back seat in public health discussions in Africa? This article brings to the forefront the pressing challenges confronting oral health across the continent. Specifically, it highlights the widespread prevalence of untreated dental diseases and the critical shortage of oral health professionals—with the number of dentists ranging from just 1.77 to as few as 0.03 per 10,000 people. Consequently, millions continue to suffer from a high burden of untreated oral conditions, including dental caries, periodontal disease, oral cancers, HIV-related complications, and noma, all of which severely compromise quality of life.

Key Insights:

  • Oral Disease Burden: Untreated dental caries and periodontal disease are widespread in Africa. Regional variations are influenced by socioeconomic and dietary factors.
  • Workforce and Policy Gaps: Many countries face a critical shortage of dentists and dental care assistants. Inadequate oral health policies worsen the problem.
  • Collaborative Solutions: Partnerships among healthcare providers, industry, civil society, and academia are key to improving oral health outcomes.
  • Prevalence of Oral disease: Untreated caries (5+ years) is highest in Northern Africa (33.72%), severe periodontal disease (15+ years) in Western Africa (26.75%), and new lip and oral cavity cancer cases in Northern Africa (median: 269.5 cases). See Table 1 for details.
Table 1: Burden of major oral diseases in Africa (Foláyan et al 2015)

Background Context:

WHO reports Africa has seen the largest global rise in oral diseases over 30 years. Nearly 44% of the population is affected. Only 57% of African countries have a national oral health policy. The region spends less than US$1 per person annually on oral health. WHO’s Global Oral Health Strategy aims for universal coverage by 2030, focusing on prevention and community-based interventions.

Implications:

  • Health Economics: Oral diseases cause significant economic losses due to healthcare costs and lost productivity. Prevention and better care access can bring long-term benefits.
  • Health Outcomes: Integrating oral health into primary healthcare and community interventions can improve overall well-being.
  • Policy and Research: Strengthening local research is vital for evidence-based policies.

To address these issues effectively, stakeholders must take coordinated action. In particular, integrating oral health into national public health policies remains essential for expanding access to care. Furthermore, national dental associations, working in partnership with public health institutions and international organisations, can drive meaningful policy change and promote better resource allocation. Through such collaborative efforts, Africa can begin to close the oral health gap and deliver improved outcomes for its population. For more details, see the original article.

 

Reference url

Recent Posts

NICE Endorses Breakthrough Bladder Cancer Treatment for Enhanced Survival

By Staff Writer

August 25, 2025

Bladder cancer treatment has recently advanced, offering new hope for adults with advanced urothelial cancer. If you’re wondering, “What is the most effective first-line bladder cancer treatment for advanced cases in the UK right now?”—the latest update is that the National Institute for Health a...
FDA Guidance on Overall Survival Assessment in Oncology Trials

By Staff Writer

August 20, 2025

Overall survival assessment serves as the gold standard for determining the true impact of oncology treatments, directly answering patient and provider questions such as: “How will this therapy affect my length of life?” According to the latest FDA guidance, robust overall survival assessment is ...
Assessment of Glofitamab With Gemcitabine in DLBCL Reveals No Additional Benefit

By João L. Carapinha

August 19, 2025

A recent G-BA decision provides a systematic evaluation of Glofitamab Gemcitabine DLBCL, combined with Gemcitabine and Oxaliplatin (GemOx), for treating adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) who are ineligible for autologous stem cell transplantation. The review...